Home LiteratureArticle Details
PMID: 18468671 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Critical issues in mucosal immunity for HIV-1 vaccine development.

The Journal of allergy and clinical immunology ·Vol. 122 ·No. 1 ·2008-07-00 ·Pages 3-9; quiz 10-1

Haynes BF, Shattock RJ

Abstract

Development of a safe and effective vaccine for HIV-1 infection is a critical global priority. However, the nature of host-virus interactions that lead to early immunosuppression and CD4 depletion, HIV-1 diversity, and the inability of the immune system to eliminate the latently infected CD4 pool of cells has to date thwarted successful vaccine development. Moreover, both the initial antibody-inducing vaccine (protein envelope gp120) and cell-mediated vaccine (recombinant adenovirus containing HIV-1 genes) strategies have failed in efficacy trials, and the latter cell-mediated vaccine appeared to have caused enhanced HIV-1 acquisition. Thus basic and translational research to understand why current vaccines have failed and elucidation of new mechanisms of virus control at mucosal surfaces is essential for eventual successful development of a preventive HIV-1 vaccine.

MeSH Terms
AIDS Vaccines/immunology Animals CD4-Positive T-Lymphocytes/immunology,virology HIV Antibodies/immunology HIV Infections/immunology,prevention & control,transmission,virology HIV-1/immunology Humans Immunity, Mucosal/immunology
Chemicals
AIDS Vaccines HIV Antibodies
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Haynes Barton F
Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. hayne002@mc.duke.edu
Shattock Robin J
References (83)
83 references, click to expand
  1. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.
    Vaccine. 2002 May 6;20(15):1922-5 PMID: 11983246
  2. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.
    AIDS. 2003 Sep 5;17(13):1871-9 PMID: 12960819
  3. Maintenance of serological memory by polyclonal activation of human memory B cells.
    Science. 2002 Dec 13;298(5601):2199-202 PMID: 12481138
  4. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.
    J Virol. 2004 Nov;78(21):11980-7 PMID: 15479838
  5. Genomics meets HIV-1.
    Nat Rev Microbiol. 2006 Nov;4(11):865-73 PMID: 17041633
  6. Fc receptor but not complement binding is important in antibody protection against HIV.
    Nature. 2007 Sep 6;449(7158):101-4 PMID: 17805298
  7. Progress and obstacles in the development of an AIDS vaccine.
    Nat Rev Immunol. 2006 Dec;6(12):930-9 PMID: 17124514
  8. Genotypic and phenotypic characterization of HIV-1 patients with primary infection.
    Science. 1993 Aug 27;261(5125):1179-81 PMID: 8356453
  9. Microbial translocation is a cause of systemic immune activation in chronic HIV infection.
    Nat Med. 2006 Dec;12(12):1365-71 PMID: 17115046
  10. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73 PMID: 9671771
  11. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Science. 2003 Jun 27;300(5628):2065-71 PMID: 12829775
  12. Diversity considerations in HIV-1 vaccine selection.
    Science. 2002 Jun 28;296(5577):2354-60 PMID: 12089434
  13. HIV vaccine design: insights from live attenuated SIV vaccines.
    Nat Immunol. 2006 Jan;7(1):19-23 PMID: 16357854
  14. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection.
    J Virol. 2005 Nov;79(22):14318-29 PMID: 16254366
  15. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan.
    PLoS Med. 2005 Feb;2(2):e25 PMID: 15740411
  16. HIV-1-induced depletion of CD4+ T cells in the gut: mechanism and therapeutic implications.
    Trends Pharmacol Sci. 2006 Jan;27(1):4-7 PMID: 16337692
  17. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Nature. 2002 Jan 17;415(6869):331-5 PMID: 11797011
  18. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.
    J Exp Med. 1998 Jul 20;188(2):233-45 PMID: 9670036
  19. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors.
    J Immunol. 2006 Apr 1;176(7):3931-41 PMID: 16547227
  20. Anti-HIV-1 ADCC: clinical and therapeutic implications.
    Biotechnol Ther. 1991;2(1-2):147-57 PMID: 1845118
  21. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
    Science. 2005 Jun 24;308(5730):1906-8 PMID: 15860590
  22. Search for the origin of HIV and AIDS.
    Science. 2000 Aug 18;289(5482):1140-1 PMID: 10970225
  23. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
    J Virol. 2008 Jan;82(1):115-25 PMID: 17942537
  24. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes.
    J Immunol. 2007 Mar 1;178(5):3177-85 PMID: 17312166
  25. T cell- and B cell-independent adaptive immunity mediated by natural killer cells.
    Nat Immunol. 2006 May;7(5):507-16 PMID: 16617337
  26. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection.
    Nat Med. 2003 Jul;9(7):847-52 PMID: 12835704
  27. Inhibiting sexual transmission of HIV-1 infection.
    Nat Rev Microbiol. 2003 Oct;1(1):25-34 PMID: 15040177
  28. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.
    Immunity. 2008 Jan;28(1):52-63 PMID: 18191596
  29. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Nature. 2002 Dec 12;420(6916):678-82 PMID: 12478295
  30. The role of membrane lipids in the induction of macrophage apoptosis by microparticles.
    Apoptosis. 2007 Feb;12(2):363-74 PMID: 17191114
  31. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody.
    J Mol Biol. 2007 Sep 7;372(1):16-22 PMID: 17631311
  32. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.
    PLoS Med. 2006 Nov;3(11):e441 PMID: 17121450
  33. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation.
    J Clin Invest. 1992 Feb;89(2):561-6 PMID: 1737846
  34. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Expert Rev Vaccines. 2006 Aug;5(4):579-95 PMID: 16989638
  35. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line.
    J Immunol. 1998 Mar 1;160(5):2145-57 PMID: 9498752
  36. Identification of host proteins required for HIV infection through a functional genomic screen.
    Science. 2008 Feb 15;319(5865):921-6 PMID: 18187620
  37. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    J Virol. 2006 Jul;80(14):6745-56 PMID: 16809280
  38. The immune geography of IgA induction and function.
    Mucosal Immunol. 2008 Jan;1(1):11-22 PMID: 19079156
  39. The clades of HIV: their origins and clinical significance.
    AIDS Rev. 2003 Oct-Dec;5(4):205-13 PMID: 15011999
  40. Coping with viral diversity in HIV vaccine design.
    PLoS Comput Biol. 2007 Apr 27;3(4):e75 PMID: 17465674
  41. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.
    Nature. 2005 Apr 28;434(7037):1093-7 PMID: 15793563
  42. Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239.
    J Virol. 2008 Apr;82(8):4154-8 PMID: 18272571
  43. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  44. HIV-1 immunopathogenesis: how good interferon turns bad.
    Clin Immunol. 2007 May;123(2):121-8 PMID: 17112786
  45. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells.
    J Exp Med. 2005 Jun 20;201(12):2023-33 PMID: 15967828
  46. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  47. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?
    Nat Rev Microbiol. 2006 Apr;4(4):312-7 PMID: 16541138
  48. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells.
    J Immunol. 2000 Nov 1;165(9):5170-6 PMID: 11046049
  49. Antibody vs. HIV in a clash of evolutionary titans.
    Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8 PMID: 16219699
  50. Antibody-based HIV-1 vaccines: recent developments and future directions.
    PLoS Med. 2007 Dec;4(12):e348 PMID: 18052607
  51. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections.
    Science. 2002 Mar 22;295(5563):2255-8 PMID: 11910108
  52. Acute HIV revisited: new opportunities for treatment and prevention.
    J Clin Invest. 2004 Apr;113(7):937-45 PMID: 15057296
  53. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  54. Recombination in HIV-1.
    Nature. 1995 Mar 9;374(6518):124-6 PMID: 7877682
  55. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
    Hum Antibodies. 2005;14(3-4):59-67 PMID: 16720975
  56. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
    Nat Med. 2007 Jan;13(1):100-6 PMID: 17187074
  57. Centralized HIV-1 envelope immunogens and neutralizing antibodies.
    Curr HIV Res. 2007 Nov;5(6):572-7 PMID: 18045113
  58. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
    J Exp Med. 2008 Jan 21;205(1):7-12 PMID: 18195078
  59. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  60. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4.
    Blood. 2007 Apr 1;109(7):2928-35 PMID: 17132727
  61. Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention.
    AIDS Res Ther. 2006 Nov 28;3:29 PMID: 17132170
  62. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.
    Nature. 1999 Feb 4;397(6718):436-41 PMID: 9989410
  63. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    J Infect Dis. 2006 Dec 15;194(12):1661-71 PMID: 17109337
  64. Improving defences at the portal of HIV entry: mucosal and innate immunity.
    PLoS Med. 2008 Apr 1;5(4):e81 PMID: 18384232
  65. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7 PMID: 18490657
  66. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses.
    J Virol. 2007 Nov;81(22):12582-95 PMID: 17728240
  67. Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin.
    J Gen Virol. 1990 Jan;71 ( Pt 1):69-76 PMID: 2303801
  68. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.
    Science. 2006 Jun 9;312(5779):1530-3 PMID: 16763152
  69. Medicine. The need for a global HIV vaccine enterprise.
    Science. 2003 Jun 27;300(5628):2036-9 PMID: 12829768
  70. Gut microbes out of control in HIV infection.
    Nat Med. 2006 Dec;12(12):1351-2 PMID: 17151687
  71. Brief but efficient: acute HIV infection and the sexual transmission of HIV.
    J Infect Dis. 2004 May 15;189(10):1785-92 PMID: 15122514
  72. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage.
    Mucosal Immunol. 2008 Jan;1(1):49-58 PMID: 19079160
  73. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    J Immunol. 2007 Apr 1;178(7):4424-35 PMID: 17372000
  74. Heterogeneity of HIV-1 and HIV-2.
    AIDS. 1995;9 Suppl A:S5-18 PMID: 8819565
  75. Target cells in vaginal HIV transmission.
    Microbes Infect. 2003 Jan;5(1):59-67 PMID: 12593974
  76. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little.
    J Virol. 2005 Jul;79(14):9228-35 PMID: 15994817
  77. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
    Virology. 2007 Sep 30;366(2):245-62 PMID: 17580087
  78. An HIV vaccine--evolving concepts.
    N Engl J Med. 2007 May 17;356(20):2073-81 PMID: 17507706
  79. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity.
    Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S161-8 PMID: 15285714
  80. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials.
    AIDS. 2003 Dec 5;17(18):2547-60 PMID: 14685049
  81. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.
    Virology. 2006 Sep 30;353(2):268-82 PMID: 17039602
  82. Marginal zone B cells in lymphocyte activation and regulation.
    Curr Opin Immunol. 2005 Jun;17(3):244-50 PMID: 15886113
  83. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
    J Clin Invest. 1995 Jul;96(1):456-64 PMID: 7615818
Article Info
Journal
The Journal of allergy and clinical immunology
Abbr.
J Allergy Clin Immunol
ISSN
1097-6825
DOI
10.1016/j.jaci.2008.03.036
Email
hayne002@mc.duke.edu
Published
2008-07-00
Epub
2008-00-12
Pages
3-9; quiz 10-1
Language
English
Region
United States
NLM ID
1275002
PMCID
PMC3014573
Subset
IM
Grants
NIAID NIH HHS · U19 AI067854 · United States
NIAID NIH HHS · U19 AI067854-05 · United States
NIAID NIH HHS · AI-0678501 · United States
External Links
PubMed source DOI: 10.1016/j.jaci.2008.03.036 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2